Myovant Sciences Cash on Hand 2017-2022 | MYOV

Myovant Sciences cash on hand from 2017 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Myovant Sciences Annual Cash on Hand
(Millions of US $)
2022 $434
2021 $685
2020 $80
2019 $156
2018 $109
2017 $181
2016 $
Myovant Sciences Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $434
2021-12-31 $528
2021-09-30 $616
2021-06-30 $570
2021-03-31 $685
2020-12-31 $746
2020-09-30 $111
2020-06-30 $100
2020-03-31 $80
2019-12-31 $99
2019-09-30 $158
2019-06-30 $227
2019-03-31 $156
2018-12-31 $183
2018-09-30 $154
2018-06-30 $144
2018-03-31 $109
2017-12-31 $129
2017-09-30 $129
2017-06-30 $154
2017-03-31 $181
2016-12-31 $192
2016-09-30 $0
2016-06-30
2016-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.236B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00